dolutegravir
For Advanced HIV, 2-Drug Dovato Regimen as Effective as 3 Drugs
The two-drug regimen of dolutegravir-lamivudine achieves comparable efficacy to three-drug therapy regimens in ...
MARCH 21, 2025
FDA Grants New Indication for Dovato to Treat Adolescents 12 and Older
The FDA granted a new indication for Dovato to treat HIV-1 infection in adolescents 12 years of age and older and ...
APRIL 10, 2024
New Studies Show Neural Tube Risk With Dolutegravir Lower Than Thought
WHO updated its global HIV treatment recommendations based on new data showing that even though dolutegravir during ...
JULY 24, 2019
FDA Approves Dovato—First 2-Drug Complete Regimen for HIV
Dovato is a single table regimen containingdolutegravir-lamivudine and is approved as a complete regimen for the ...
APRIL 8, 2019
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
FDA Warns of Neural Tube Birth Defects With Dolutegravir
The FDA issued an alert about serious cases of neural tube birth defects involving the brain, spine and spinal cord ...
MAY 18, 2018
2-Drug Combination Effective in Maintaining Viral Suppression in HIV Patients
The requirement of lifelong treatment for HIV infection has highlighted a need to minimize cumulative drug ...
FEBRUARY 17, 2017
